Jubilant Ingrevia Q4 FY26 Revenue Up 12% to ₹1,179 Cr, Recommends Final Dividend ₹2.50/Share
Jubilant Ingrevia's Q4 FY26 revenue grew 12% YoY to ₹1,179 crore, with EBITDA up 11% YoY to ₹172 crore. PAT rose 17% YoY to ₹86 crore. The company recommended a final dividend of ₹2.50 per share, totaling ₹5 per share for FY26. Key highlights include successful dispatch from the new Agro CDMO facility and the acquisition of Remidex Pharma.
The announcement includes key financial results (revenue, EBITDA, PAT), a dividend declaration, and strategic business updates (new facility, acquisition) which are material information for investors and can significantly influence stock performance.
The company reported strong year-on-year growth in revenue and EBITDA, recommended a significant dividend, and highlighted strategic achievements like a new facility dispatch and an acquisition, indicating positive business performance and future outlook.
Jubilant Ingrevia Limited reported a healthy performance for the quarter and financial year ended March 31, 2026. The company's total revenue for Q4 FY26 stood at ₹1,179 crore, marking a 12% year-on-year increase, driven by a 10% volume growth. EBITDA for the quarter was ₹172 crore, up 11% year-on-year and 26% quarter-on-quarter. Profit After Tax (PAT) after exceptional items was ₹86 crore, an increase of 17% year-on-year and 84% quarter-on-quarter. The company's net debt to EBITDA improved to 0.99x, with net debt reducing by 11% in FY26.
Commenting on the performance, the Chairmen highlighted the effective handling of the Middle East crisis, with no force majeure and zero production loss. Key achievements for the quarter include successful dispatch from the newly constructed Agro CDMO facility and the acquisition of Remidex to accelerate growth in the Human Nutrition business. The Board has recommended a final dividend of ₹2.50 per share (250%), bringing the total dividend for FY26 to ₹5 per share (500%).
The Specialty Chemicals segment reported revenue of ₹516 crore, a 6% year-on-year increase, with EBITDA at ₹139 crore and margins around 27%. The Nutrition & Health Solutions segment saw revenue of ₹230 crore, up 21% year-on-year, with EBITDA at ₹32 crore. The Chemical Intermediates segment revenue was ₹433 crore, up 15% year-on-year, with EBITDA growth supported by cost pass-through.
Looking ahead to FY27, the company expects growth to be led by Specialty Chemicals and Nutrition, with a recovery in Acetyls. Jubilant Ingrevia anticipates sequential growth in revenue and EBITDA starting from Q1 FY27. The construction of the Gajraula Multi Purpose Plant (MPP) is progressing well, which will further strengthen the CDMO growth roadmap. The company will host an earnings call at 5:00 PM IST on May 26, 2026.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.